Maestros Electronics & Telecommunications Systems Limited (METSL) Fair Value & Analysis
Healthcare · IN · Market cap ₹737M
Fair value as of: Jul 5, 2026
From 17 valuation models · updated today
Share price −2.7% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹110.70 – ₹178.20 · fair‑value band ₹105.16 – ₹272.44 · the ₹133.70 price screens below the ₹217.47 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Maestros Electronics & Telecommunications Systems Limited (METSL) currently trades at ₹133.70, while our model-based Fair Value estimate is ₹217.47 — implying the stock looks roughly 62.7% undervalued today. We read business quality at 55/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Maestros Electronics & Telecommunications Systems Limited generated revenue of ₹394M at a net margin of 18.4%. Revenue grew 51.7% year over year. It earns a return on equity of 18.8%. Net debt stands at ₹13.3M. Fundamentals as of Jul 5, 2026
Our scenario range runs from ₹105.16 (bear case) to ₹272.44 (bull case); at ₹133.70, the current price sits within that range. The share trades about 28% below its 52-week high and 26% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside — at 63%, METSL screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Maestros Electronics & Telecommunications Systems Limited manufactures and sells medical equipment and telemedicine products in India. It operates through two segments, Electronics and Instrumentation, and Telemedicine. The company offers critical care products, such as ECG machines, patient monitors, defibrillators, pulse oximeters, spirometer, syringe pumps, and stress test machines; mother and child care products, including fetal monitors; and telemedicine solutions. Maestros Electronics & Telecommunications Systems Limited was incorporated in 2010 and is based in Mumbai, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Maestros Electronics & Telecommunications Systems Limited reported revenue of ₹394M in FY2026 versus ₹111M in FY2022, a compound +37.1%/yr. Reported net income was ₹72.5M in FY2026, compounding +55.1%/yr from FY2022.
Is METSL fairly valued? → Check now
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | 1,600 MXN | 82.40 MXN | -95% |
| Stryker Corporation S1YK34 | R$79.18 | R$43.78 | -45% |
| Medtronic plc MDT | $79.27 | $73.33 | -7% |
| Boston Scientific Corporation B1SX34 | R$229.30 | R$43.33 | -81% |
| Edwards Lifesciences Corporation EW | $87.45 | $41.02 | -53% |
| Siemens Healthineers AG SEMHF | $40.29 | $47.96 | +19% |
| GE HealthCare Technologies Inc GEHC | $60.64 | $65.03 | +7% |
| DexCom, Inc DXCM | $69.07 | $65.56 | -5% |
| Koninklijke Philips N.V 1PHIA | €24.31 | €9.97 | -59% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥144.39 | ¥105.08 | -27% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Maestros Electronics & Telecommunications Systems Limited (METSL) undervalued?
What is the fair value of METSL?
What is the quality score of METSL?
What is the revenue of Maestros Electronics & Telecommunications Systems Limited (METSL)?
What is the net profit margin of METSL?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.